Randomized Trialhigh evidence
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.
JAMA cardiology·May 1, 2026·PMID 41911489
Why it mattersATTR-CM is progressive and fatal; evidence of durable mortality and hospitalization reduction with near-complete transthyretin stabilization supports early, uninterrupted treatment. The sustained benefit and biomarker stabilization reinforce acoramidis as a long-term disease-modifying strategy.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled